Last reviewed · How we verify

Calcineurin Inhibitor

Milton S. Hershey Medical Center · FDA-approved active Small molecule

Calcineurin Inhibitor is a Calcineurin inhibitor Small molecule drug developed by Milton S. Hershey Medical Center. It is currently FDA-approved for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis). Also known as: Tacrolimus (Prograf), Cyclosporine (Gengraf), Mycophenolic Acid (Myfortic), Prograf, Tacrolimus, Cyclosporine.

Calcineurin inhibitors block the phosphatase enzyme calcineurin, preventing T cell activation and proliferation by inhibiting the transcription of pro-inflammatory cytokines.

Calcineurin inhibitors block the phosphatase enzyme calcineurin, preventing T cell activation and proliferation by inhibiting the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis).

At a glance

Generic nameCalcineurin Inhibitor
Also known asTacrolimus (Prograf), Cyclosporine (Gengraf), Mycophenolic Acid (Myfortic), Prograf, Tacrolimus, Cyclosporine, Tacrolimus, Cyclosporin, NeoOral, Prograf
SponsorMilton S. Hershey Medical Center
Drug classCalcineurin inhibitor
TargetCalcineurin (protein phosphatase 2B)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Calcineurin inhibitors bind to immunophilins (cyclophilin or FK-binding protein) and form a complex that inhibits calcineurin phosphatase activity. This prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing IL-2 and other cytokine production essential for T cell proliferation and immune response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Calcineurin Inhibitor

What is Calcineurin Inhibitor?

Calcineurin Inhibitor is a Calcineurin inhibitor drug developed by Milton S. Hershey Medical Center, indicated for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis).

How does Calcineurin Inhibitor work?

Calcineurin inhibitors block the phosphatase enzyme calcineurin, preventing T cell activation and proliferation by inhibiting the transcription of pro-inflammatory cytokines.

What is Calcineurin Inhibitor used for?

Calcineurin Inhibitor is indicated for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis, rheumatoid arthritis).

Who makes Calcineurin Inhibitor?

Calcineurin Inhibitor is developed and marketed by Milton S. Hershey Medical Center (see full Milton S. Hershey Medical Center pipeline at /company/milton-s-hershey-medical-center).

Is Calcineurin Inhibitor also known as anything else?

Calcineurin Inhibitor is also known as Tacrolimus (Prograf), Cyclosporine (Gengraf), Mycophenolic Acid (Myfortic), Prograf, Tacrolimus, Cyclosporine, Tacrolimus, Cyclosporin, NeoOral, Prograf.

What drug class is Calcineurin Inhibitor in?

Calcineurin Inhibitor belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Calcineurin Inhibitor in?

Calcineurin Inhibitor is FDA-approved (marketed).

What are the side effects of Calcineurin Inhibitor?

Common side effects of Calcineurin Inhibitor include Nephrotoxicity, Hypertension, Neurotoxicity (tremor, headache), Hyperglycemia, Gingival hyperplasia, Increased infection risk.

What does Calcineurin Inhibitor target?

Calcineurin Inhibitor targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related